Authors
    • Hematology and Oncology
    • Gastrointestinal oncology
    Oncologist in Cleveland
    Oncologist in Cleveland
    • Professor of Medicine at Cleveland Clinic Lerner College of Medicine

    Alok A. Khorana, MD, FACP, FASCO, is Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, the Sondra and Stephen Hardis Chair in Oncology Research, Vice-Chair for Clinical Services of the Taussig Cancer Institute (part of Case Comprehensive Cancer Center) and Director of the Gastrointestinal Malignancies Program at the Cleveland Clinic, Cleveland, Ohio. His clinical and translational research program focuses on predictive factors and drug development in cancer-associated thrombosis and gastrointestinal cancers and has been funded by grants from the National Cancer Institute, the National Heart, Lung, and Blood Institute, the Hardis Family, the Porter Family Fund, VeloSano, the Cleveland Clinic Center for Excellence, the Scott Hamilton CARES Initiative, Stand Up To Cancer (Colorectal Cancer “Dream Team”) and the V Foundation.

    Dr. Khorana received his medical degree from Maharaja Sayajirao University’s Medical College in Baroda (now Vadodara, Gujarat), India. His postdoctoral training included a residency in internal medicine at the University at Buffalo in New York and a fellowship in hematology/oncology at the University of Rochester, New York. He is a Fellow of the American College of Physicians and in 2018 was elected Fellow of the American Society of Clinical Oncology.

    Dr. Khorana is Past Chair of the American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines Panel (CPGC), Chair of ASCO CPGC’s Pancreas Cancer Working Group, Co-Chair of ASCO CPGC’s Multisite Advisory Group and Co-Chair of the ASCO Guidelines Panel on Resectable Pancreas Cancer. He has also served or serves on the ASCO Scientific Program Committee and multiple Guidelines/Guidance Panels including those of ASCO, American Society of Hematology (ASH), American Society for Radiation Oncology and International Society on Thrombosis and Haemostasis (ISTH). He was previously Chair of the ISTH Scientific Subcommittee on Hemostasis and Malignancy He has previously served as a member of the US Pharmacopoeia Oncology Expert Committee.  

    Dr. Khorana has been published in a variety of journals including New England Journal of Medicine, Journal of American Medical Association (JAMA), Journal of Clinical Oncology, Blood, Journal of the National Cancer Institute, Clinical Cancer Research, PLoS One, and JAMA Internal Medicine. He has co-authored chapters in multiple textbooks including multiple editions of Cecil Essentials of Medicine and DeVita’s Cancer: Principles and Practice of Oncology. He is co-editor of the book Cancer-Associated Thrombosis: New Findings in Translational Science, Prevention and Treatment (Informa, 2007). Dr. Khorana’s fiction and creative nonfiction works have been published in the Bellevue Literary Review, Annals of Internal Medicine and Health Affairs and selected for Best American Medical Writing (Kaplan, 2009). 

    • Medical Oncology
    Oncologist, pancreas cancer, translational/clinical investigator, genomics, IRB, Data and safety monitoring
    Oncologist, pancreas cancer, translational/clinical investigator, genomics, IRB, Data and safety monitoring
    • Section Head for Hepatopancreaticobiliary and Neuroendocrine Cancers, Gastrointestinal Oncology Service, Associate Director for the David M. Rubenstein Center for Pancreatic Cancer at Memorial Sloan-Kettering Cancer Center

    Dr. Eileen M. O’Reilly serves as the Section Head for Hepatopancreaticobiliary and Neuroendocrine Cancers, Gastrointestinal Oncology Service, Associate Director for the David M. Rubenstein Center for Pancreatic Cancer at Memorial Sloan Kettering (MSK), and is an Attending Physician and Member at MSK and Professor of Medicine at Weill Cornell Medical College. Dr. O’Reilly holds the Winthrop Rockefeller Endowed Chair in Medical Oncology.

    Dr. O’Reilly received her medical degree at Trinity College (Dublin University) in Ireland, where she was born. She completed her residency training in Ireland and Fellowship training at MSK. Dr. O’Reilly has pancreatic and hepatobiliary malignancies as the major focus of her research and clinical activities. Research directions include integration of molecular and genetic-based therapies for the treatment of pancreas cancer along with development of adjuvant and neoadjuvant therapies and identification of for therapy selection.

    Dr. O’Reilly teaches and mentors oncology fellows, junior faculty, residents and house-staff and has numerous teaching and other awards. Dr. O’Reilly is the Principal Investigator of multiple trials in pancreas cancer and has authored/co-authored > 250 articles, editorials and book chapters. Dr. O’Reilly’s other responsibilities include: Chair of MSK’s Institutional Review & Privacy Board (IRB-B), Chair of the Data and Safety Monitoring Committee (DSMC) and Chair of the Continuing Medical Education (CME) committee. Nationally Dr. O’Reilly is the Co-Chair of the NCI Alliance Co-Operative Group Gastrointestinal Cancers Committee, and serves on the Medical and Scientific Advisory Board of the Pancreatic Cancer Action Network, NCCN Pancreas panel, ASCO Guidelines Committee and the Board of the National Pancreas Foundation. 

  • Marc Carrier, MD, MSc, FRCPC, is a Professor in the Faculty of Medicine, Department of Medicine, a Senior Scientist in the Clinical Epidemiology Program of The Ottawa Hospital Research Institute and Vice-Chair of Research for the Department of Medicine. He holds a Tier 2 Research Chair in Venous Thromboembolism and Cancer from the University of Ottawa. His clinical research is focused in venous thromboembolic disease and cancer, including cancer screening, prevention and management.

    • Internal Medicine

    Dr. Le Gal is a Professor in the Division of Hematology of the Department of Medicine at the University of Ottawa, a physician in the Thrombosis Program, Division of Hematology at The Ottawa Hospital, and a Senior Scientist in the Ottawa Hospital Research Institute, Clinical Epidemiology Program. 

    He was born and trained in France. He received his M.D. degree from the University of Brest in 1997, and completed his residency in Internal Medicine in 2004. He received a Ph.D. degree in Clinical Epidemiology from the University of Brest in 2007. He received fellowship training in Internal Medicine in Brest University Hospital, France, in Angiology in Geneva University Hospital, Switzerland, and completed a clinical and research fellowship in the Thrombosis Program at the University of Ottawa in 2008. Dr. Le Gal went back to France and was appointed a Professor of Internal Medicine at Brest University, before being appointed at the Ottawa Hospital Research Institute in 2012.

    Dr. Le Gal’s primary research interest is the diagnosis and management of venous thromboembolism (VTE). He studied the diagnostic value of signs and symptoms for the diagnosis of VTE. Relevant to this application, he developed a clinical decision rule for PE diagnosis in emergency room patients, a clinical decision rule for the diagnosis of DVT in the primary care setting, and participated in the development of a clinical decision rule for recurrent VTE. He also has been involved in many studies that provided external validation for previously derived clinical decision rules. Finally, he developed and validated management strategies for VTE based on the use of these clinical decision rules. Dr. Le Gal has more than 300 peer-reviewed publications in general internal medicine and specialized journals. He is a member of the international advisory board of the Journal of Thrombosis and Haemostasis, and a reviewer for main general internal medicine and thrombosis Journals. He has been the principal investigator of several multicenter multinational projects on the diagnosis and management of VTE.

  • I am a hematologist with a particular interest in benign hematologic disorders. I have extensive experience in the diagnosis and management of thrombotic diseases and also hemorrhagic disorders. This is particularly helpful for the complex population of patients with cancer who are at risk for both thrombosis and bleeding. My research interests include studies of the interaction of the coagulation system and cancer. I have published a number of papers in the field, including both clinical and basic science studies. I also actively contribute to the training of students and house officers.